BDBM562795 (S)-2-((2R,3S,6R)-2,3-Bis(4-chlorophenyl)-5-oxo-6-(pyridin-4-ylmethyl)morpholino)pentanoic acid and (R)-2-((2S,3R,6S)-2,3-bis(4-chlorophenyl)-5-oxo-6-(pyridin-4-ylmethyl)morpholino)pentanoic acid::US11407721, Example 42

SMILES CCC[C@@H](N1[C@@H]([C@@H](O[C@@H](Cc2ccncc2)C1=O)c1ccccc1)c1ccc(Cl)cc1)C(O)=O

InChI Key InChIKey=YZWHVSJCIRIEHU-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 562795   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562795(US11407721, Example 42 | (S)-2-((2R,3S,6R)-2,3-Bis...)
Affinity DataIC50: 947nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562795(US11407721, Example 42 | (S)-2-((2R,3S,6R)-2,3-Bis...)
Affinity DataIC50: 539nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent